TYRA Tyra Biosciences Inc

P/E --
Forward P/E --
Price/Sales --
Beta 0.751
Div Yield --
Market Cap --

Company Analysis

Latest News

Tyra Biosciences Inc Q3 2026 Earnings Preview: What Analysts Expect on November 11, 2026

Tyra Biosciences is expected to report a Q3 2026 consensus loss of $0.66 per share on $0 revenue, with its current $21.15 share price trading significantly...

Tyra Biosciences Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026

Tyra Biosciences is expected to report a Q3 2026 loss of $0.67 per share on zero revenue, with the current stock price of $21.52 trading significantly below...

TYRA Biosciences Announces Pricing of $400 Million Underwritten Public Offering

Tyra Biosciences, Inc. has entered into an underwriting agreement for a public offering of common stock and pre-funded warrants, with expected gross proceeds...

TYRA Announces Positive Phase 2 Data for Dabogratinib in Bladder Cancer Trial

Tyra Biosciences announced positive initial results from its SURF302 Phase 2 study of oral dabogratinib for treating FGFR3-altered non-muscle invasive bladder...

Farallon Capital Opens Major New $137M Position in Tyra Biosciences

Farallon Capital Management has established a new, significant stake in Tyra Biosciences (TYRA), a clinical-stage biotechnology company. According to its...

Farallon Capital exits TYRA Biosciences, liquidating $137M position

In a significant portfolio shift, Farallon Capital Management fully exited its position in TYRA Biosciences (TYRA), a clinical-stage biotech company. According...